论文部分内容阅读
美国FDA已经对Ortho-Mcneil公司的避孕透皮传递系统———Ortho Evra(Norelgestromin和乙炔雌二醇的复方透皮贴剂)提出警告,因为有数据表明,与其常规的口服制剂相比,这种透皮贴剂引起非致命性血栓形成的危险性增加了2倍。FDA此次发布的“警告”内容包括2项由Ortho-Mcneil公司进
The U.S. FDA has warned Ortho-Mcneil’s contraceptive transdermal delivery system, Ortho Evra (a compound transdermal patch of Norelgestromin and ethinyl estradiol), because data show that compared with its conventional oral formulations, Transdermal patches cause a two-fold increase in the risk of non-fatal thrombosis. FDA’s “warning” release includes two items entered by Ortho-Mcneil